About US
Contact us
-
Dillon, who shaped NICE into an influential gatekeeper, ready to exit CEO postTwenty years after its founding, England’s National Institute for Health and Care Excellence (NICE) has established itself as perhaps the world’s preeminent drug cost watchdog. Now, the only leader i2019/8/19
-
Roche's Hemlibra scores funding to treat much larger group of patients in EnglandRoche’sHemlibrahas been storming out of the gate since its first approval in 2017. Now, it's set to benefit a much wider patient group in England thanks to new funding from health authorities there.2019/8/19
-
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasisEli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis. Taltz met the p2019/8/16
-
CureVac and Yale University to develop mRNA-based lung therapiesBiopharmaceutical firm CureVac has signed a collaborative research agreement with US-based Yale University to discover new therapeutic candidates for the treatment of pulmonary diseases. The partners2019/8/15
-
AstraZeneca announces breakthrough therapy status for Calquence in CLLAstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL). The i2019/8/15
-
Boehringer partners with MD Anderson on virtual R&D centreBoehringer Ingelheim has collaborated with The University of Texas MD Anderson Cancer Center to create a joint Virtual Research and Development Center focused on oncology research. The new initiative2019/8/14
-
Progress made in developing first Chlamydia vaccineResearchers from Statens Serum Institut (SSI), Denmark, and Imperial College London have published promising results from the first clinical trial of a vaccine for Chlamydia, the most common sexually2019/8/14
-
Jazz Pharmaceuticals acquires Cavion in $312.5m dealIrish biopharmaceutical company Jazz Pharmaceuticals has acquired US-based biotechnology firm Cavion for a total potential sum of $312.5m. The deal, which makes Cavion a wholly-owned subsidiary of Ja2019/8/13
-
US Senator seeks records linked to Novartis’ Zolgensma data issuesThe US Senate Finance Committee Chairman Chuck Grassley has asked Novartis to provide information on data manipulation issues related to the company’s subsidiary AveXis’ spinal muscular atrophy (SMA)2019/8/13
-
Sonnet BioTherapeutics agrees to buy Relief TherapeuticsBiotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under a binding share exchange agreement with Relief Therapeutics Holding. Under the t2019/8/12